1. Introduction {#sec1-marinedrugs-16-00312}
===============

Xanthones, usually obtained from many marine-derived fungi, are a class of secondary metabolites containing a polysubstituted 9*H*-xanthen-9-one skeleton \[[@B1-marinedrugs-16-00312]\]. They are described as "privileged structures" in the field of modern medicine \[[@B2-marinedrugs-16-00312]\], due to their pronounced pharmacological activities, including antibacterial \[[@B3-marinedrugs-16-00312]\], antifungal \[[@B4-marinedrugs-16-00312]\], cancer chemopreventive \[[@B5-marinedrugs-16-00312],[@B6-marinedrugs-16-00312]\], and cytotoxic activities \[[@B7-marinedrugs-16-00312]\]. Among them, prenylxanthones have been mainly isolated from the fungi of the genus *Aspergillus*/*Emericella* \[[@B8-marinedrugs-16-00312],[@B9-marinedrugs-16-00312],[@B10-marinedrugs-16-00312]\]. The first prenylxanthone derivative, tajixanthone, was isolated from the fungus *Aspergillus variecolor* by Chexal et al. in 1974 \[[@B11-marinedrugs-16-00312]\]. Since then, about 20 bioactive prenylxanthone analogues have been obtained, including ruguloxanthones A--C \[[@B12-marinedrugs-16-00312]\] and emerixanthones A--D \[[@B10-marinedrugs-16-00312]\].

In our previous investigation on the marine-derived fungus *Aspergillus* sp. ZA-01, several new cytotoxic 14,15-hydroxylated prenylxanthones, aspergixanthones A--H were obtained from cultures grown in rice solid medium \[[@B9-marinedrugs-16-00312]\]. Fungal strains are reported to produce an array of constituents when grown under different cultivation conditions \[[@B13-marinedrugs-16-00312]\], including variations in the composition of culture medium, period of cultivation, the pH, and the temperature. Different HPLC-UV profiles of the EtOAc extract were obtained when fermentation of strain ZA-01 was carried out using a shaken Czapek-Dox medium. Further systematic chemical exploration of this extract led to the isolation of three new prenylxanthone derivatives, aspergixanthones I--K (**1**--**3**), and four known analogues: aspergixanthone A (**4**) \[[@B9-marinedrugs-16-00312]\], 15-acetyl tajixanthone hydrate (**5**) \[[@B14-marinedrugs-16-00312]\], tajixanthone hydrate (**6**) \[[@B15-marinedrugs-16-00312]\], and 16-chlorotajixanthone (**7**) \[[@B15-marinedrugs-16-00312]\] ([Figure 1](#marinedrugs-16-00312-f001){ref-type="fig"}). Herein, we report the isolation, structure elucidation, absolute configurations, and anti-*Vibrio* activities of these compounds (**1**--**7**).

2. Results {#sec2-marinedrugs-16-00312}
==========

Aspergixanthone I (**1**) was obtained as a yellow powder, which showed five maximum UV absorbance bands at 228, 242, 264, 285, and 385 nm, indicating a prenylxanthone nucleus for **1** \[[@B8-marinedrugs-16-00312],[@B9-marinedrugs-16-00312],[@B10-marinedrugs-16-00312]\]. The molecular formula of C~27~H~30~O~8~ for **1** was deduced from the molecular ion peak \[M + Na\]^+^ at *m/z* 505.1827 (calculated (calcd.) for C~27~H~30~O~8~Na, 505.1833) in positive HRESIMS, which corresponded to 13 degrees of unsaturation. The ^1^H NMR and ^13^C NMR data of **1** ([Table 1](#marinedrugs-16-00312-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00312-t002){ref-type="table"}), showed the presence of four methyl signals (*δ*~H~ 2.38 (3H, s, H-24), 1.86 (3H, s, H-23), 1.38 (3H, s, H-18), and 1.34 (3H, s, H-17); *δ*~C~ 26.9 (C-17), 25.3 (C-18), 22.5 (C-23), and 17.4 (C-24)), one oxygen-bearing methylene signal (*δ*~H~ 4.46 (1H, brd, *J* = 10.8 Hz, H-19a) and 4.35 (1H, dd, *J* = 12.0, 10.8 Hz, H-19b); *δ*~C~ 64.1 (C-19)), three aromatic methine signals (*δ*~H~ 7.41 (1H, d, *J* = 8.4 Hz, H-3), 7.29 (1H, s, H-5), and 6.71 (1H, d, *J* = 8.4 Hz, H-2); *δ*~C~ 137.9 (C-3), 119.5 (C-5), and 109.5 (C-2)), and one keto carbonyl signal (*δ*~C~ 184.5 (C-13)), confirming the prenylxanthone skeleton of **1** \[[@B8-marinedrugs-16-00312],[@B9-marinedrugs-16-00312],[@B10-marinedrugs-16-00312]\]. In fact, the structure of **1** was closely related to that of compound epitajixanthone hydrate, a prenylxanthone derivative that was previously isolated from the endophytic fungus *Emericella* sp. XL029 \[[@B8-marinedrugs-16-00312]\]. Additional signals for an acetoxy (*δ*~H~ 1.99 (3H, s); *δ*~C~ 170.4 and 20.7) were present in the NMR spectra of **1**, implicating an epitajixanthone hydrate analogue bearing an additional acetoxy group for **1**. The position of this 15-OAc unit was deduced from the proton spin system of H-14/H-15 from the ^1^H-^1^H COSY spectrum ([Figure S4](#app1-marinedrugs-16-00312){ref-type="app"}), and the long-range couplings of H-15/15-COCH~3~ and H-18/C-15 in the HMBC spectrum ([Figure S5](#app1-marinedrugs-16-00312){ref-type="app"}) of **1** ([Figure 2](#marinedrugs-16-00312-f002){ref-type="fig"}). Thus, **1** was the 15-acetyl derivative of epitajixanthone hydrate.

In order to define the relative and absolute configurations of **1**, the methanolysis derivative of **1** (**1a**) was prepared using K~2~CO~3~ in anhydrous MeOH. The NMR data of **1a** were identical to those of epitajixanthone hydrate, suggesting that **1a** and epitajixanthone hydrate were the same compound, and that **1** and epitajixanthone hydrate had the same stereoconfiguration. This deduction was verified by the NOESY correlation ([Figure S6](#app1-marinedrugs-16-00312){ref-type="app"}) between H-20 and H-25 in **1**, and the positive specific rotation value (\[α\]${}_{20}^{D}$ = +42.5 (*c* 0.10, MeOH)) of **1** \[[@B8-marinedrugs-16-00312],[@B9-marinedrugs-16-00312]\]. Additionally, the same ECD cotton effects of **1** and epitajixanthone hydrate (**1a**) ([Figure 3](#marinedrugs-16-00312-f003){ref-type="fig"}a) indicated that **1** had the same stereoconfiguration as epitajixanthone hydrate (**1a**), whose relative configuration was determined using crystal data (Mo *K*α radiation) \[[@B8-marinedrugs-16-00312]\]. To assign the absolute configuration of **1a**, the dimolybdenum tetraacetate (Mo~2~(AcO)~4~) ICD procedure (Snatzke's method) was used. The positive ICD cotton effects at 300 (0.10) and 400 (0.34) nm of **1** gave the Newman form of the Mo-complexes of **1** ([Figure 3](#marinedrugs-16-00312-f003){ref-type="fig"}b), which showed a clockwise rotation, and suggested a 15*S* configuration for **1a** \[[@B16-marinedrugs-16-00312],[@B17-marinedrugs-16-00312]\]. Based on the above data analysis, the absolute configuration of **1** could be defined as 15*S*,20*R*,25*R*.

Aspergixanthone J (**2**) showed an \[M + Na\]^+^ ion peak at *m/z* 517.1826, indicating a molecular formula of C~28~H~30~O~8~. The NMR data of **2** ([Table 1](#marinedrugs-16-00312-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00312-t002){ref-type="table"}) closely resembled those of aspergixanthone A (**4**) \[[@B9-marinedrugs-16-00312]\], except for the signals for the 17-Me in aspergixanthone A (**4**) being replaced by those for an olefinic methylene (*δ*~H~ 4.65 (1H, brs, H-17a) and 4.62 (1H, brs, H-17b); *δ*~C~ 114.8 (C-17)), indicating the presence of a double bond between C-16 and C-17 in **2**. Analysis of HMBC correlations from H-17 to C-15/C-16/C-18 demonstrated the elucidation of the plane structure of **2**. The NOESY correlations ([Figure S16](#app1-marinedrugs-16-00312){ref-type="app"}), the coupling constants, the negative specific rotation value of **2**, and the similarity of the ECD spectra of **2** and **4** ([Figure 4](#marinedrugs-16-00312-f004){ref-type="fig"}) suggested that **2** had the same absolute configuration as **4**, which was previously assigned as 14*R*,15*R*,20*S*,25*R* by a combined analysis of ECD, ORD, and VCD methods \[[@B9-marinedrugs-16-00312]\]. In particular, the absolute configuration at C-15 in **4** was demonstrated to be *R*, using Snatzke's method ([Figure 3](#marinedrugs-16-00312-f003){ref-type="fig"}b), unambiguously, which was opposite to **1**.

Aspergixanthone K (**3**) was determined to have a molecular formula of C~26~H~28~O~7~ using HRESIMS analysis. The 1D and 2D NMR data of **3** ([Table 1](#marinedrugs-16-00312-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00312-t002){ref-type="table"}) revealed that **3** represents a structural analogue of **2**, but it is missing the acetoxy group at C-25. The unambiguous ^1^H-^1^H COSY cross-peaks of 25-OH/H-25/H-20/H-19 confirmed the postulated 25-deacetylation homologue of **2**. Similar NOESY correlations ([Figure S23](#app1-marinedrugs-16-00312){ref-type="app"}) and ECD spectra of **2** and **3** implied that they had the same stereoconfigurations.

Prenylxanthone derivatives (**1**--**7**) are a class of bioactive natural compounds that belong to the family of naturally occurring xanthones \[[@B1-marinedrugs-16-00312]\]. These prenylxanthones with a C-4 terpenoid-derived side chain were mainly isolated from fungi of the genus *Aspergillus*/*Emericella* \[[@B8-marinedrugs-16-00312],[@B9-marinedrugs-16-00312],[@B10-marinedrugs-16-00312]\]. It was an interesting and challenging task to define the stereoconfigurations of the C-4 side chain for these prenylxanthone derivatives. In particular, the absolute configuration at C-15 in prenylxanthone derivatives was often assigned by comparison of the specific rotation with that of previous reports \[[@B8-marinedrugs-16-00312],[@B14-marinedrugs-16-00312]\], which was inappropriate, since the absolute configuration of C-15 had nothing to do with specific rotation \[[@B9-marinedrugs-16-00312]\]. In this work, two possible absolute configurations for C-15 were present in different prenylxanthone derivatives, which were assigned using Snatzke′s method.

*Vibrio* spp., such as *Vibrio anguillarum*, *Vibrio parahemolyticus*, and *Vibrio alginolyticus*, are a class of Gram-negative halophilic bacteria that usually occur in marine and coastal environments throughout the world, which could lead to vibriosis in crustaceans and cause serious damage to mariculture production \[[@B18-marinedrugs-16-00312],[@B19-marinedrugs-16-00312]\]. However, there is no effective vaccine to prevent vibriosis due to lacking adaptive immunity in crustacean species. In the past few decades, searching for anti-*Vibrio* agents from marine-derived fungi for controlling vibriosis has become one of the research trends. Therefore, the anti-*Vibrio* activities against *V.* *parahemolyticus*, *V. anguillarum*, and *V.* *alginolyticus* of **1**--**7** were tested. All of the compounds (**1**--**7**) showed anti-*Vibrio* activities to three pathogenic *Vibrio* spp., with MIC values between 1.56 and 25.0 μM ([Table 3](#marinedrugs-16-00312-t003){ref-type="table"}). Among them, aspergixanthone I (**1**) exhibited the strongest anti-*Vibrio* activity, indicating that the propenyl at C-20 with *α*-stereoconfiguration may play an important role for the anti-*Vibrio* activity.

3. Experimental Section {#sec3-marinedrugs-16-00312}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00312}
------------------------------------

Specific rotations: AA-55 series polarimeter (Optical Activity Ltd., Cambridgeshire, UK). UV spectra: a multiskan go microplate spectrophotometer (Thermo Scientific Co., Waltham, MA, USA). Electronic circular dichroism curves: J-815 spectropolarimeter (JASCO Electric Co., Ltd., Tokyo, Japan). IR spectra: Nicolet NEXUS 470 spectrophotometer (Thermo Electron Co., Madison, WI, USA) using KBr pellets. 1D and 2D NMR spectra: Bruker AVIII 600 MHz NMR spectrometer (Bruker BioSpin GmbH Co., Rheinstetten, Germany), using the residual solvent resonance as an internal standard. Semi-preparative HPLC: Shimadzu LC-20AT system with a SPD-M20A photodiode array detector (Shimadzu Co., Kyoto, Japan), and Waters RP-18 (XBridge OBD, 5 μm, 10 mm × 250 mm).

3.2. Isolation of the Fungal Material {#sec3dot2-marinedrugs-16-00312}
-------------------------------------

The fungus *Aspergillus* sp. ZA-01 has been previously described \[[@B9-marinedrugs-16-00312]\]. Liquid fermentation of the fungus *Aspergillus* sp. ZA-01 using shaken Czapek-Dox medium (150 rpm, 30 L, 1 L Erlenmeyer flasks each containing 500 mL of culture broth) was performed at 30 °C for 14 days. The culture was filtered to separate the culture broth from the mycelia and was repeatedly extracted using EtOAc (10 L) at room temperature six times, which yielded a crude extract (3.2 g). The extract was then chromatographed on a silica gel column using a stepwise gradient of petroleum ether (PE)/EtOAc (100:0 to 0:100) to produce six fractions: Fr.1--Fr.6. Fr.3 was further purified by silica gel CC (PE:EtOAc = 2:1), Sephadex LH-20 (CH~2~Cl~2~:MeOH = 1:1), and preparative HPLC using a C~18~ column (CH~3~OH:H~2~O = 73:27) to provide **1** (5.2 mg, *t*~R~ 20.5 min), **2** (2.0 mg, *t*~R~ 28.4 min), **3** (2.3 mg, *t*~R~ 25.1 min), **4** (4.6 mg, *t*~R~ 13.6 min), **5** (6.2 mg, *t*~R~ 16.2 min), **6** (5.0 mg, *t*~R~ 11.0 min), and **7** (4.1 mg, *t*~R~ 22.3 min).

Aspergixanthone I (**1**): yellow, amorphous powder; \[α\]${}_{20}^{D}$ = +42.5 (*c* 0.10, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 230 (4.5), 243 (4.0), 266 (4.7), 285 (2.1), 382 (1.9) nm; IR (KBr) *ν*~max~ 3451, 2930, 2356, 1637, 1593, 1462, 1257, 1081, 903 cm^--1^; NMR data, see [Table 1](#marinedrugs-16-00312-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00312-t002){ref-type="table"}; HRESIMS *m/z* 505.1827 \[M + Na\]^+^, (calcd. for C~27~H~30~O~8~Na, 505.1833).

Aspergixanthone J (**2**): yellow, amorphous powder; \[α\]${}_{20}^{D}$ = −78.2 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 233 (4.7), 242 (4.1), 265 (5.0), 287 (2.2), 383 (2.0) nm; IR (KBr) *ν*~max~ 3449, 2920, 2362, 1651, 1579, 1428, 1274, 1040, 867 cm^--1^; NMR data, see [Table 1](#marinedrugs-16-00312-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00312-t002){ref-type="table"}; HRESIMS *m/z* 517.1826 \[M + Na\]^+^, (calcd. for C~28~H~30~O~8~Na, 517.1833).

Aspergixanthone K (**3**): yellow, amorphous powder; \[α\]${}_{20}^{D}$ = −94.0 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 232 (4.0), 243 (3.8), 267 (4.3), 286 (1.7), 384 (1.5) nm; IR (KBr) *ν*~max~ 3439, 2954, 2371, 1663, 1543, 1460, 1269, 1069, 935 cm^--1^; NMR data, see [Table 1](#marinedrugs-16-00312-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00312-t002){ref-type="table"}; HRESIMS *m/z* 453.1912 \[M + Na\]^+^, (calcd. for C~26~H~29~O~7~, 453.1908).

3.3. Preparation of the Methanolysis Derivative (***1a***) of ***1*** {#sec3dot3-marinedrugs-16-00312}
---------------------------------------------------------------------

A solution of **1** (3.0 mg) and K~2~CO~3~ (10.0 mg) in anhydrous MeOH (3 mL) was stirred at room temperature for 5 h. The mixture was evaporated to dryness, and then purified using a silica gel column (PE/EtOAc, 1:1) to give the methanolysis derivative **1a** (2.5 mg).

Methanolysis derivative (**1a**): yellow, amorphous powder; ^1^H NMR (CDCl~3~, 600 MHz) *δ* 12.59 (1H, s, 1-OH), 7.52 (1H, d, *J* = 7.8 Hz, H-3), 7.23 (1H, s, H-5), 6.75 (1H, d, *J* = 7.8 Hz, H-2), 5.48 (1H, brs, H-25), 5.05 (1H, s, H-22a), 4.78 (1H, s, H-22b), 4.46 (1H, dd, *J* = 9.6, 1.8 Hz, H-19a), 4.32 (1H, dd, *J* = 10.2, 9.6 Hz, H-19b), 3.75 (1H, d, *J* = 9.6 Hz, H-15), 3.19 (1H, d, *J* = 13.8 Hz, H-14a), 2.68 (1H, dd, *J* = 13.8, 9.6 Hz, H-14b), 2.55 (1H, brd, *J* = 12.0 Hz, H-20), 2.36 (3H, s, H-24), 1.98 (3H, s, H-23), 1.43 (3H, s, H-18), and 1.35 (3H, s, H-17); ^13^C NMR (CDCl~3~, 150 MHz) *δ* 184.4 (C, C-13), 160.6 (C, C-1), 153.3 (C, C-10), 151.9 (C, C-11), 149.5 (C, C-7), 142.3 (C, C-21), 138.8 (C, C-6), 138.3 (CH, C-3), 121.7 (C, C-8), 119.4 (CH, C-5), 116.9 (C, C-12), 116.3 (C, C-4), 111.8 (CH~2~, C-22), 110.1 (CH, C-2), 109.4 (C, C-9), 77.9 (CH, C-15), 73.2 (C, C-16), 64.2 (CH~2~, C-19), 61.5 (CH, C-25), 44.1 (CH, C-20), 32.1 (CH~2~, C-14), 26.7 (CH~3~, C-18), 23.7 (CH~3~, C-17), 22.6 (CH~3~, C-23), and 17.6 (CH~3~, C-24); HRESIMS *m/z* 441.1906 \[M + H\]^+^, (calcd. for C~25~H~29~O~7~, 441.1908).

3.4. Snatzke's Method {#sec3dot4-marinedrugs-16-00312}
---------------------

The ICD spectra of **1a** and **4** were obtained after addition of Mo~2~(OAc)~4~ following a previously referenced procedure \[[@B16-marinedrugs-16-00312],[@B17-marinedrugs-16-00312]\].

3.5. Anti-Vibrio Activity Assays {#sec3dot5-marinedrugs-16-00312}
--------------------------------

Anti-*Vibrio* activity was evaluated by the conventional broth dilution assay \[[@B20-marinedrugs-16-00312]\]. Three pathogenic *Vibrio* strains, *Vibrio parahemolyticus, Vibrio anguillarum*, and *Vibrio* *alginolyticus* were used, and ciprofloxacin was used as a positive control with MIC values of 0.078 μM, 0.312 μM, and 0.625 μM, respectively. Replicates were maintained for each test bacteria.

4. Conclusions {#sec4-marinedrugs-16-00312}
==============

Seven prenylxanthone derivatives, including three new compounds (**1**--**3**), were obtained from the marine-derived fungus *Aspergillus* sp. ZA-01 by using a shaken Czapek-Dox medium. The absolute configuration of **1** was determined by the Mo~2~(AcO)~4~ ICD method. This work suggested that the OSMAC approach was an active pathway for the exploration of new bioactive molecules.

The following are available online at <http://www.mdpi.com/1660-3397/16/9/312/s1>. Figures S1--S24: 1D and 2D NMR, and mass spectra of **1**--**3**.

###### 

Click here for additional data file.
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![COSY and key HMBC correlations of **1**.](marinedrugs-16-00312-g002){#marinedrugs-16-00312-f002}

![(**a**) Experimental ECD spectra for **1** and **1a**; (**b**) ICD spectra of Mo-complexes of **1a** (red) and **4** (blue) recorded in DMSO.](marinedrugs-16-00312-g003){#marinedrugs-16-00312-f003}

![Experimental ECD spectra for **2**--**4**.](marinedrugs-16-00312-g004){#marinedrugs-16-00312-f004}

marinedrugs-16-00312-t001_Table 1

###### 

^1^H NMR data (*δ*) of **1**--**3** (600 MHz, *δ* in ppm, CDCl~3~, *J* in Hz).

  Position                1                      2                      3
  ----------------------- ---------------------- ---------------------- ----------------------
  2                       6.71, d (8.4)          6.80, d (8.4)          6.85, d (8.4)
  3                       7.41, d (8.4)          7.60, d (8.4)          7.65, d (8.4)
  5                       7.29, s                7.27, s                7.24, s
  14                      3.33, dd (14.4, 2.4)   4.82, d (8.4)          4.83, d (8.4)
  2.91, dd (14.4, 10.8)                                                 
  15                      5.15, dd (10.8, 2.4)   4.19, d (8.4)          4.19, d (8.4)
  17                      1.34, s                4.65, brs              4.64, brs
  4.62, brs               4.60, brs                                     
  18                      1.38, s                1.76, s                1.77, s
  19                      4.46, brd (10.8)       4.56, brd (11.4)       4.43, dd (10.8, 3.0)
  4.35, dd (12.0, 10.8)   4.32, dd (11.4, 3.0)   4.35, dd (10.8, 3.0)   
  20                      2.55, d (12.0)         2.72, brs              2.72, d (3.0)
  22                      5.06, s                4.81, s                4.81, s
  4.78, s                 4.76, s                4.59, s                
  23                      1.86, s                1.89, s                1.85, s
  24                      2.38, s                2.36, s                2.37, s
  25                      5.50, brs              6.90, brs              5.43, brs
  1-OH                    12.63, brs             13.06, brs             12.83, brs
  14-OCH~3~               \-                     3.28, s                3.30, s
  15-OAc                  1.99, s                \-                     \-
  25-OH                   4.51, brs              \-                     4.96, d (4.2)
  25-OAc                  \-                     2.10, s                \-

marinedrugs-16-00312-t002_Table 2

###### 

^13^C NMR data (*δ*) of **1**--**3** (150 MHz, *δ* in ppm, CDCl~3~).

  Position      1              2              3
  ------------- -------------- -------------- --------------
  1             161.1, C       162.0, C       161.8, C
  2             109.5, CH      110.7, CH      110.7, CH
  3             137.9, CH      134.7, CH      135.1, CH
  4             115.1, C       115.4, C       115.8, C
  5             119.5, CH      120.4, CH      119.1, CH
  6             139.0, C       138.0, C       139.0, C
  7             149.6, C       150.4, C       149.9, C
  8             121.8, C       115.0, C       121.4, C
  9             109.2, C       109.0, C       108.8, C
  10            153.3, C       153.5, C       153.7, C
  11            151.8, C       151.8, C       152.0, C
  12            116.9, C       116.4, C       116.9, C
  13            184.5, C       183.4, C       184.5, C
  14            29.7, CH~2~    78.7, CH       78.8, CH
  15            78.6, CH       80.0, CH       80.0, CH
  16            72.5, C        141.7, C       142.5, C
  17            26.9, CH~3~    114.8, CH~2~   114.8, CH~2~
  18            25.3, CH~3~    18.2, CH~3~    18.2, CH~3~
  19            64.1, CH~2~    63.9, CH~2~    64.8, CH~2~
  20            44.1, CH       42.6, CH       45.1, CH
  21            142.3, C       142.5, C       142.7, C
  22            111.7, CH~2~   112.9, CH~2~   112.4, CH~2~
  23            22.5, CH~3~    22.6, CH~3~    22.7, CH~3~
  24            17.4, CH~3~    17.5, CH~3~    17.7, CH~3~
  25            61.0, CH       65.7, CH       63.3, CH
  14-OCH~3~     \-             57.2, CH~3~    57.2, CH~3~
  15-OAc        170.4, C       \-             \-
  20.7, CH~3~                                 
  25-OAc        \-             170.2, C       \-
  21.4, CH~3~                                 

marinedrugs-16-00312-t003_Table 3

###### 

Tests of anti-*Vibrio* activities for compounds **1**--**7**.

  Strains                Compounds \[MIC (μM)\]                                             
  ---------------------- ------------------------ ------ ------ ------ ------ ------ ------ -------
  *V. parahemolyticus*   1.56                     6.25   3.12   25.0   12.5   6.25   25.0   0.078
  *V. anguillarum*       1.56                     25.0   25.0   25.0   25.0   6.25   6.25   0.312
  *V. alginolyticus*     3.12                     25.0   12.5   25.0   12.5   12.5   25.0   0.625

[^1]: These authors contributed equally to this work.
